HLA-A24-restricted cancer antigen peptides

Details HLA-A24-restricted cancer antigen peptides HLA-A24-restricted cancer antigen peptides

2003-06-12

2008-09-02

Tsang, Cecilia (Department: 1654)

Chemistry: natural resins or derivatives; peptides or proteins;

Peptides of 3 to 100 amino acid residues

8 to 10 amino acid residues in defined sequence

C514S002600

Reexamination Certificate

active

07420034

ABSTRACT:
HLA-A24-restricted peptides derived from WT1 which have an activity to induce CTLs in vivo, polynucleotides encoding said peptides, cancer vaccines using those peptides or polynucleotides in vivo or in vitro, or the like are provided. The cancer vaccines of the present invention may be used to treat many cancer patients.

REFERENCES:
patent: 6034235 (2000-03-01), Sugiyama et al.
patent: 2003/0092656 (2003-05-01), Sugiyama
patent: 2004/0097703 (2004-05-01), Sugiyama
patent: 2004/0247609 (2004-12-01), Sugiyama
patent: 2005/0002951 (2005-01-01), Sugiyama et al.
patent: 2005/0266014 (2005-12-01), Sugiyama et al.
patent: 1 103 564 (2001-05-01), None
patent: WO-00/18795 (2000-04-01), None
Oka, Yoshihiro et al., “Human Cytotoxic T-lymphocyte responses specific for peptides of the Wild-type Wilms' tumor gene (WT1) Product”, Immunogenetics, vol. 51, No. 2, pp. 99-107, 2000.
Kubo, Ralph T. et al., “Definitiion of Specific Peptide Motifs for Four Major HLA-A Alleles1”, The American Association of Immunologists, vol. 152, pp. 3913-3924, 1994.
U.S. Appl. No. 10/517,600, filed Dec. 13, 2004, Sugiyama, et al.
U.S. Appl. No. 10/562,486, filed Dec. 27, 2005, Sugiyama.
U.S. Appl. No. 11/322,245, filed Jan. 3, 2006, Sugiyama, et al.
U.S. Appl. No. 10/527,692, filed Mar. 11, 2005, Sugiyama.
U.S. Appl. No. 10/528,360, filed Mar. 18, 2005, Sugiyama, et al.
U.S. Appl. No. 11/196,452, filed Aug. 4, 2005, Sugiyama, et al.
U.S. Appl. No. 10/541,821, filed Jul. 11, 2005, Sugiyama, et al.
U.S. Appl. No. 09/744,815, filed Jan. 30, 2001, Sugiyama, et al.
Azuma, T. et al., British Journal of Haematology, vol. 116, pp. 601-603, (2002).
Ohminami, H. et al., Blood, vol. 95, No. 1, pp. 286-292, Jan. 1, 2000.
Rosenberg, S. et al., Immunity, vol. 10, pp. 281-287, Mar. 1999.
Bakker, A. et al., J. Exp. Med., vol. 179, pp. 1005-1009, Mar. 1994.
Kawakami, Y. et al., Proc. Natl. Acad. Sci. USA, vol. 91, pp. 3515-3519, Apr. 1994.
Brichard, V. et al., J. Exp. Med., vol. 178, pp. 489-495, Aug. 1993.
Fisk, B. et al., J. Exp. Med., vol. 181, pp. 2109-2117, Jun. 1995.
Tsang, K. et al., J. Natl. Cancer Inst. vol. 87, pp. 982-990, Jul. 5, 1995.
Correale, P. et al., J. Natl. Cancer Inst. vol. 89, No. 4, 293-300, Feb. 19, 1997.
Melief, C. et al., Cur. Opin. Immunol., vol. 5, pp. 709-713, (1993).
Pardoll, D., Cur. Opin. Immunol., vol. 5, pp. 719-725, (1993).
Nanda, N. et al., Cell, vol. 82, pp. 13-17, Jul. 14, 1995.
Melief, C. et al., Immunol. Rev., vol. 146, pp. 167-177, (1995).
Gessler, M. et al., Nature, vol. 343, pp. 774-778, Feb. 22, 1990.
Call, K. et al., Cell, vol. 60, pp. 509-520, (1990).
Oka, Y. et al., J. Immunol., vol. 164, pp. 1873-1880, (2000).
Tsuboi, A. et al., J. Clin. Immunol., vol. 20, No. 3, pp. 195-202, (2000).
The 31st Annual Meeting of the Japanese Society for Immunology, p. 160, 2-C-W11-8-P Abstract enclosed.
Azuma, T., et al., “Identification of a Novel WT1-Derived Pepetide Which Induces Human Leucocyte Antigen-A24-Restricted Anti-Leukaemia Cytotoxic T Lymphocytes”, British Journal of Haematology, Mar. 2002, vol. 116, No. 3, pp. 601 to 603.
Ohminami, H., et al., “HLA Class I-Restricted Lysis of Leukemia Cells by a CD8+Cytotoxic T-Lymphocyte Clone Specific for WT1 Peptide”, Blood, Jan. 2000, vol. 95, No. 1, pp. 286 to 292.

Affiliated with

Also associated with

Rating

HLA-A24-restricted cancer antigen peptides does not yet have a rating. At this time, there are no reviews or comments for this patent.

If you have personal experience with HLA-A24-restricted cancer antigen peptides, we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and HLA-A24-restricted cancer antigen peptides will most certainly appreciate the feedback.

Rate now

Comments { 0 }

Profile ID: LFUS-PAI-O-3991104